MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- ASTRAZENECA PHARMA
ASTRAZENECA PHARMA Share Price (AIDL)
Here is the latest stock price and chart of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.
Get Details: First Stock to Potentially Accumulate Rs 7 Crore Long-term Wealth
| Live BSE Quotes | Feb 25, 2021 (Close) | ||
|---|---|---|---|
| Price (Rs)3,508.55 | Open (Rs) 3,535.00 | High (Rs) 3,535.00 | Low (Rs) 3,502.00 |
| % Change0.44 | Volume 3,600 | Value (Rs) 12,656,278 | 52-Week H/L 4,970.00 / 1,888.00 |
| Live NSE Quotes | Feb 25, 2021 (Close) | ||
|---|---|---|---|
| Price (Rs)3,505.60 | Open (Rs) 3,535.85 | High (Rs) 3,535.85 | Low (Rs) 3,500.00 |
| % Change0.56 | Volume 15,028 | Value (Rs) 52,855,799 | 52-Week H/L 4,970.00 / 1,885.00 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day 0.44% | 1 Month -2.42% | 3 Months -22.15% | 1 Year 28.58% | 5 Years (CAGR)* 24.61% | 10 Years (CAGR)* 12.03% |
* Compound Annual Growth Rate
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 30.24 | P/E Ratio (x) 116.02 | Market Cap (Rs m) 87,713.75 | P/BV (x) 35.52 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
ASTRAZENECA PHARMA Share Price Today:
ASTRAZENECA PHARMA last traded price was up 0.4% to Rs 3,508.6 on the BSE. On the NSE, ASTRAZENECA PHARMA last traded price was up 0.6% to Rs 3,505.6. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.8%. And the benchmark S&P BSE SENSEX was at 51,039.3 (up 0.5%).
Over the last 30 days, the ASTRAZENECA PHARMA share price is down 2.4%. And over the last one year, ASTRAZENECA PHARMA share price is up 27.4%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)
Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.
Related Views On News
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)
Sep 22, 2020 | Updated on Sep 22, 2020For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
More Views on NewsMost Popular
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Penny Stock Master Series: The Quest for 10X Profits in 10 Years (Profit Hunter)
Feb 12, 2021This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
MoreOUR TOP 5 IDEAS
- Access Now: Eight Steps to Your Eight Figure Fortune
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - ALEMBIC PHARMA COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.